Compare KMDA & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMDA | FLGT |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.6M | 525.3M |
| IPO Year | 2013 | 2016 |
| Metric | KMDA | FLGT |
|---|---|---|
| Price | $7.67 | $16.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $14.00 | ★ $28.33 |
| AVG Volume (30 Days) | 45.6K | ★ 510.4K |
| Earning Date | 05-13-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $13.94 | $10.09 |
| Revenue Next Year | $9.84 | $12.18 |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.50 | $13.46 |
| 52 Week High | $9.35 | $31.04 |
| Indicator | KMDA | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 52.84 |
| Support Level | $6.60 | $15.39 |
| Resistance Level | $7.85 | $16.70 |
| Average True Range (ATR) | 0.21 | 0.66 |
| MACD | -0.06 | 0.13 |
| Stochastic Oscillator | 21.92 | 84.98 |
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.